Evoke Pharma Inc. (NASDAQ:EVOK)‘s stock had its “outperform” rating reissued by FBR & Co in a research report issued to clients and investors on Friday. They presently have a $9.00 price target on the specialty pharmaceutical company’s stock. FBR & Co’s price objective suggests a potential upside of 411.36% from the company’s current price.

A number of other research firms also recently weighed in on EVOK. Noble Financial reissued a “hold” rating on shares of Evoke Pharma in a research report on Tuesday, August 16th. HC Wainwright set a $2.50 price objective on Evoke Pharma and gave the company a “hold” rating in a report on Tuesday, August 16th. Finally, Zacks Investment Research raised Evoke Pharma from a “hold” rating to a “buy” rating and set a $2.50 price objective on the stock in a report on Wednesday, October 5th. Two equities research analysts have rated the stock with a sell rating, five have issued a hold rating and two have issued a buy rating to the stock. The company presently has a consensus rating of “Hold” and an average price target of $9.88.

Analyst Recommendations for Evoke Pharma (NASDAQ:EVOK)

Evoke Pharma (NASDAQ:EVOK) opened at 1.76 on Friday. The firm’s 50-day moving average price is $1.82 and its 200-day moving average price is $3.53. The company’s market capitalization is $21.74 million. Evoke Pharma has a 52 week low of $1.35 and a 52 week high of $11.11.

Evoke Pharma (NASDAQ:EVOK) last released its earnings results on Wednesday, November 9th. The specialty pharmaceutical company reported ($0.29) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.26) by $0.03. During the same period last year, the business earned ($0.42) earnings per share. On average, equities analysts expect that Evoke Pharma will post ($1.32) earnings per share for the current year.

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. State Treasurer State of Michigan purchased a new position in Evoke Pharma during the second quarter worth about $171,000. Vanguard Group Inc. boosted its position in Evoke Pharma by 5.0% in the second quarter. Vanguard Group Inc. now owns 62,381 shares of the specialty pharmaceutical company’s stock valued at $427,000 after buying an additional 2,947 shares during the period. Finally, Bank of New York Mellon Corp boosted its position in Evoke Pharma by 2.0% in the second quarter. Bank of New York Mellon Corp now owns 23,679 shares of the specialty pharmaceutical company’s stock valued at $162,000 after buying an additional 464 shares during the period. Institutional investors own 9.15% of the company’s stock.

Evoke Pharma Company Profile

Evoke Pharma, Inc is a specialty pharmaceutical company. The Company is focused primarily on the development of drugs to treat gastrointestinal (GI) disorders and diseases. The Company is developing EVK-001, a metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women.

5 Day Chart for NASDAQ:EVOK

Receive News & Stock Ratings for Evoke Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evoke Pharma Inc. and related stocks with our FREE daily email newsletter.